Adstiladrin data shown at end of Nov at big UroOncology meet
I don't see the poster available online from their presentation but there are some interesting points.
The protocol allows them to keep treating responders ever 3months AFTER the initial 4 dose protocol. So they are still treating the responders, just not sure how many till see posters. So some/many/all (?) get the main study treatment every 3 months for years(?).
Despite that, of the 55 responders from the initial 103 patients, they get steady fall off in patients who are disease free.
High grade disease recurrence free numbers are
3 months - 55 patients
6 months - 42
9 months - 36
12 months - 25
24 months - 20
36 months - 14 ( 13.5% CR rate if you use the original 103 patients)
Any bladder cancer disease free numbers are worse
3 months - 55 patients
6 months - 38
9 months - 36
12 months - 25
24 months - 15
36 months - 12 (11.6% CR rate if you use the original 103 patients.
However, they are very sneaky in how they sell it. The wording is 25% keep their CR. As in, of the 55 who responded at all at 3m, 25% kept their response. Not that impressive to me.
https://www.urotoday.com/conference-highlights/suo-2023/suo-2023-bladder-cancer/148294-suo-2023-efficacy-of-intravesical-nadofaragene-firadenovec-vcng-for-patients-with-bacillus-calmette-guerin-unresponsive-carcinoma-in-situ-of-the-bladder-36-month-follow-up-from-a-phase-3-trial.html